IL17A and cystic fibrosis: The IL-17A reduction was significant for CF/Chronic PA patients in response to SEB (p = 0.0007) and PA Hi (p = 0.0386), and for CF/Intermittent-Free PA patients in response to PHA (p = 0.0420), SEB (p = 0.0096), PA Hi (p = 0.0292) and PA Lo (p = 0.0137).